Intas Marbomet 150mg Advanced Veterinary Fluoroquinolone Antibacterial Tablets for Dogs & Cats – Marbofloxacin 150mg (Blister Strip of 6 Tablets)

Active Pharmaceutical Matrix & Pharmacological Actions

Active ConstituentStrength per TabletPharmacological ClassTherapeutic Target & Biological Mode of ActionMarbofloxacin IP150.0 mgSynthetic 3rd-Generation Fluoroquinolone AntibacterialInhibits bacterial DNA gyrase (Topoisomerase II) and Topoisomerase IV; disrupts DNA replication and repair; bactericidal against Gram(-) (E. coli, Pseudomonas, Proteus, Klebsiella, Pasteurella) and Gram(+) (Staphylococcus pseudintermedius).Tablet Excipient BaseBase q.s. to 1 TabletCompressed Oral MatrixEnsures rapid gastric disintegration, consistent systemic absorption, and high bioavailability.

Clinical Veterinary Indications

• Complicated Skin & Soft-Tissue Infections: Deep pyoderma, furunculosis, cellulitis, infected bite lacerations, and draining interdigital sinus tracts.

• Complicated Urinary Tract Infections (UTIs): Recurrent bacterial cystitis, pyelonephritis, and bacterial prostatitis caused by susceptible E. coli or Proteus mirabilis.

• Severe Lower Respiratory Infections: Bacterial bronchopneumonia, chronic bronchitis, and secondary bacterial infections complicating kennel cough.

• Perioperative Surgical Coverage: Prophylaxis and therapy in contaminated orthopedic, soft-tissue, and reconstructive surgeries under culture guidance.

Comparison: Intas Marbomet vs. Cefpet CLV vs. Enrofloxacin

ParameterIntas Marbomet 150mg (Current)Intas Cefpet CLV 325mgGeneric Enrofloxacin (150mg)Drug Class3rd-Gen FluoroquinolonePotentiated 3rd-Gen Cephalosporin2nd-Gen FluoroquinolonePrimary MechanismDNA Gyrase & Topoisomerase IV BlockadeCell wall peptidoglycan synthesis blockadeDNA Gyrase inhibitionKilling KineticsConcentration-Dependent ($C_{\max}/\text{MIC}$)Time-Dependent ($T > \text{MIC}$)Concentration-DependentActivity Against PseudomonasModerate to HighLow / InactiveModerateFeline Retinal SafetyHigh Margin of Ocular SafetySafeNarrow (Documented risk of retinal blindness)Dosing FrequencyOnce Daily (SID)Once Daily (SID)Once Daily (SID) or Divided BID

Dosage & Administration Guidelines

Administer orally strictly under licensed veterinary prescription based on verified body weight:

• Standard Veterinary Dosing Parameters:

  • Standard Clinical Range: Typically dosed at 2.0 mg to 5.5 mg Marbofloxacin per kg body weight, administered once daily (every 24 hours).

  • In severe, deep-seated, or Pseudomonas soft-tissue infections, veterinarians may prescribe up to the higher end of the therapeutic range (5.5 mg/kg once daily).

• Weight-Based Dosing Reference Guide for Marbomet 150mg Tablets:

Pet Body Weight RangeTypical Daily Dosage (at ~2.75–5.5 mg/kg basis)Clinical Context12 kg to 15 kg1/4 to 1/2 Tablet once dailyMedium dogs / monitored large cats under specialist direction25 kg to 30 kg1/2 to 1 Tablet once dailyStandard large breeds (Labradors, Boxers, Dalmatians)40 kg to 55 kg1 to 1.5 Tablets once dailyGiant breeds (German Shepherds, Rottweilers, Great Danes)

• Administration Instructions:

  • Give directly into the mouth, or disguise the tablet within a small portion of wet food or boiled meat.

  • Avoid Dairy at Dosing Time: Do not administer with milk, paneer, curd, or calcium/iron supplements (Intas Intacal Pet Max or Feritas Pet). Divalent cations chelate marbofloxacin in the gut lumen, reducing systemic absorption.

  • COURSE COMPLETION (MANDATORY): Complete the full prescribed course (typically 5 to 10 days for standard UTIs/wounds; 21 to 42 days for deep pyoderma). Discontinuing treatment early when outward symptoms improve promotes the survival of resistant bacterial strains.

Product Specifications

ParameterDetailsBrandIntas Pharmaceuticals Ltd. (Intas Animal Health - PET Division)Product Trade NameMarbomet 150mg TabletsProduct ClassificationAdvanced Veterinary Fluoroquinolone Systemic AntibacterialActive CompositionMarbofloxacin IP (150 mg per tablet)Dosage FormCompressed Oral TabletsPackaging SizeBlister Strip of 6 TabletsTarget SpeciesDogs and Cats (Under strict veterinary prescription)Therapeutic ClassSystemic Antibacterial / DNA-Gyrase InhibitorPrescription StatusSchedule H / Veterinary Prescription Medicine (Rx required)

Safety Warnings, Precautions & Contraindications

• Prescription Only (Rx): Schedule H antibacterial. Must be dispensed and administered under veterinary diagnosis, ideally supported by bacterial culture and sensitivity testing.

• Rapid Growth & Cartilage Precaution (Canines): Fluoroquinolones carry a documented risk of causing articular cartilage erosions and arthropathies in rapidly growing pediatric dogs. Contraindicated in small/medium puppies under 8 months of age, and in large/giant breed puppies under 12 to 18 months of age whose growth plates remain open.

• Central Nervous System Precaution: Use with caution in pets with a diagnosed history of epilepsy, severe hepatic encephalopathy, or active seizure disorders, as fluoroquinolones may lower seizure thresholds.

• Gastrointestinal Tolerability: Mild, self-limiting digestive signs (soft stools, reduced appetite, transient vomiting) may occasionally occur. Dosing with a light non-dairy meal reduces digestive sensitivity.

• Probiotic Spacing: When administering concurrent probiotics (such as Intas Guts-Up), separate doses by at least 2 to 3 hours to prevent antibiotic inactivation of the live beneficial flora.

• Storage: Store below 25°C in a dry place protected from heat, direct sunlight, and moisture. Keep tablets sealed in their original blister foil until administration. Keep strictly out of reach of children and domestic pets.